News & Updates

Early antiretroviral therapy (ART) in individuals with HIV offers better outcomes, particularly in those aged 35 years and younger, in a follow-up analysis of the START trial. Conversely, delayed therapy results in a higher risk of death and serious health issues in this population.

Patients who are refractory or intolerant to currently approved antifungal therapies exhibited a positive response to the novel triterpenoid antifungal ibrexafungerp, according to interim analysis results of the phase III FURI trial.

Among people with potential nonoccupational exposure to HIV, a single-tablet once-daily regimen (STR) of doravirine-lamivudine-tenofovir disoproxil is a well-tolerated postexposure prophylaxis (PEP) option, reports a study presented at the recently concluded 2022 HIV Glasgow Conference.

Implementing the bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment regimen in routine clinical care can effectively suppress HIV in people living with HIV over 24 months of follow-up, reports a study presented at HIV Glasgow 2022.

Antibiotics are commonly inappropriately prescribed for upper respiratory tract infections (URTIs), reports a recent Egypt study. Nevertheless, physicians show good attitudes toward appropriate antibiotic use and knowledge of antibiotic resistance.

Inpatient management of skin and soft tissue infections (SSTIs) often uses substantial healthcare resources, but identification of outpatient candidates and avoidance of tests with low diagnostic capacity can reduce the economic burden of SSTIs, suggests a study.